WOBURN, Mass.--(BUSINESS WIRE)--June 20, 2006--ArQule, Inc. (NASDAQ: ARQL - News) today announced the enrollment and successful dosing of the first patient in a Phase 2 clinical trial of ARQ 501 in combination with gemcitabine to treat pancreatic cancer.
